BR112015001275A2 - preparação para o tratamento da tuberculose - Google Patents

preparação para o tratamento da tuberculose

Info

Publication number
BR112015001275A2
BR112015001275A2 BR112015001275-2A BR112015001275A BR112015001275A2 BR 112015001275 A2 BR112015001275 A2 BR 112015001275A2 BR 112015001275 A BR112015001275 A BR 112015001275A BR 112015001275 A2 BR112015001275 A2 BR 112015001275A2
Authority
BR
Brazil
Prior art keywords
preparation
tuberculosis
treatment
storage
toxicity
Prior art date
Application number
BR112015001275-2A
Other languages
English (en)
Inventor
Gumeniuk
Ivanovich Mykola
Original Assignee
Gumeniuk, Mykola Ivanovich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gumeniuk, Mykola Ivanovich filed Critical Gumeniuk, Mykola Ivanovich
Publication of BR112015001275A2 publication Critical patent/BR112015001275A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo “preparação para o tratamento da tuberculose” a preparação para o tratamento da tuberculose refere-se à indústria química e farmacêutica e da medicina. a preparação para o tratamento de tuberculose, a qual contém a isoniazida como a substância activa e água para injecção como componente auxiliar, de acordo com a invenção contém, adicionalmente, como componentes auxiliares, metionina, ácido succínico e succinato de sódio. a nova composição da preparação torna possível aumentar a temperatura de armazenamento da referida preparação, o que é importante no transporte e armazenamento dos mesmos, e também para diminuir a toxicidade do seu efeito sobre o corpo durante o tratamento da tuberculose. 1/1
BR112015001275-2A 2012-07-20 2013-07-22 preparação para o tratamento da tuberculose BR112015001275A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
UA201208962 2012-07-20
UAU201208962 2012-07-20
PCT/UA2013/000079 WO2014014434A1 (ru) 2012-07-20 2013-07-22 Препарат для лечения туберкулеза

Publications (1)

Publication Number Publication Date
BR112015001275A2 true BR112015001275A2 (pt) 2018-01-30

Family

ID=56889302

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015001275-2A BR112015001275A2 (pt) 2012-07-20 2013-07-22 preparação para o tratamento da tuberculose

Country Status (6)

Country Link
AP (1) AP2015008270A0 (pt)
BR (1) BR112015001275A2 (pt)
EA (1) EA025861B1 (pt)
RU (1) RU2648822C2 (pt)
UA (1) UA74095U (pt)
WO (1) WO2014014434A1 (pt)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
EA021968B1 (ru) * 2009-05-28 2015-10-30 Общество С Ограниченной Ответственностью "Институт Гиалуаль" Лекарственное средство для внутрикожного введения

Also Published As

Publication number Publication date
EA025861B1 (ru) 2017-02-28
UA74095U (ru) 2012-10-10
RU2015106366A (ru) 2016-09-10
RU2648822C2 (ru) 2018-03-28
WO2014014434A1 (ru) 2014-01-23
AP2015008270A0 (en) 2015-02-28
EA201590243A1 (ru) 2015-06-30

Similar Documents

Publication Publication Date Title
BR112015001419A8 (pt) composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
DOP2016000071A (es) Inhibidores de tirosina cinasa de bruton
BR112016002171A2 (pt) método, composição estéril e injetável e método para preparar uma composição estéril e injetável
BR112018015273A2 (pt) derivados de benzimidazol como moduladores de ror-gama
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
BR112017026159A2 (pt) inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer
BR112015020302A2 (pt) derivado de pirazol
BR112013006953A2 (pt) composto, composições farmacêutica e anti-helmíntica, uso de um composto, kit, e, método de tratamento de uma doença
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
GT201400285A (es) Formulacion de anticuerpos
BR112015016001A2 (pt) compostos, composições farmacêuticas e respectivos usos e método para tratar ou prevenir infecção bacteriana
BR112015026238A8 (pt) composto dihidropirazino-pirazina, composição farmacêutica que o compreende, uso do composto, métodos para inibir ou medir a fosforilação e para inibir a atividade da proteína quinase, bem como kit
BR112015022092A8 (pt) derivado de di-hidropiridazina-3,5-diona, seu uso e agente preventivo e/ou terapêutico comprendendo o mesmo
BR112012018695A2 (pt) compostos pirazol como antagonistas crth2
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
BR112015025805A2 (pt) compostos de ligação de nh3 e métodos para inibir o transporte de fosfato
BR112015019412A2 (pt) inibidores de bace1
PE20151810A1 (es) Composiciones farmaceuticas que comprenden everolimus
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
BR112014009506A2 (pt) composição médica de eperisona estabilizada e preparação estabilizada de liberação sustentada contendo eperisona
GT201700220A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap)
CY1120892T1 (el) Σκευασματα δοσολογιας τροποποιητη υποδοχεα οπιοειδων
BR112014016472A2 (pt) formulação farmacêutica estável para administração oral que compreende levocetirizina ou um sal farmaceuticamente aceitável da mesma e montelukast ou um sal farmaceuticamente aceitável do mesmo
BR112018002115A2 (pt) benzamidas aneladas
BR112018001035A2 (pt) compostos de fenoxiacetamidas aneladas, sal farmaceuticamente aceitável, seu método de síntese, combinação de medicamento e uso dos mesmos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2524 DE 21-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.